日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

纤溶酶原激活物抑制剂-1介导非小细胞肺癌对PD-1抗免疫疗法的耐受性。

期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-24-0890
Sumii Masahiko, Masuda Takeshi, Shimoji Kiyofumi, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Mimae Takahiro, Nakashima Taku, Iwamoto Hiroshi, Miyata Yoshihiro, Hamada Hironobu, Okada Morihito, Miyata Toshio, Hattori Noboru
肺癌
细胞生物学
PD-1
发表日期：2026
文献求助 收藏

Risk factors for postextubation pneumonia using diagnosis procedure combination and claims data in Japan

日本利用诊断程序组合和索赔数据分析拔管后肺炎的风险因素

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-026-44666-3
Hirayama, Junko; Nakamori, Masahiro; Matsumoto, Akihiro; Chen, Sanmei; Yoshikawa, Kohei; Horimasu, Yasushi; Ota, Kohei; Miyoshi, Hirotsugu; Shimpuku, Yoko; Sato, Yoko
肺炎
发表日期：2026
文献求助 收藏

Effectiveness and safety of combination immunotherapy with or without ipilimumab according to PD-L1 expression in patients with non-small cell lung cancer: a multi-center retrospective cohort study

根据PD-L1表达情况评估联合免疫疗法（含或不含伊匹木单抗）治疗非小细胞肺癌患者的有效性和安全性：一项多中心回顾性队列研究

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-2025-aw-1281
Nomura, Akio; Masuda, Takeshi; Shimoji, Kiyofumi; Takao, Shun; Izumi, Yusuke; Araki, Yusuke; Takayama, Yusuke; Masuda, Ken; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Iwamoto, Hiroshi; Senoo, Tadashi; Shoda, Hiroyasu; Ishikawa, Nobuhisa; Yamasaki, Masahiro; Hamada, Hironobu; Okada, Morihito; Hattori, Noboru
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Tumor-Bearing Status Accelerates Bleomycin-Induced Pulmonary Inflammation via Endothelial Activation.

肿瘤状态通过内皮细胞活化加速博来霉素诱导的肺部炎症。

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.70272
Isoyama Shoko, Yamaguchi Kakuhiro, Iwamoto Hiroshi, Horimasu Yasushi, Funaishi Kunihiko, Shimoji Kiyofumi, Sakamoto Shinjiro, Masuda Takeshi, Nakashima Taku, Ohshimo Shinichiro, Hamada Hironobu, Hattori Noboru
肺癌
细胞生物学
内皮细胞
Immunology/Inflammation
炎症
发表日期：2026
文献求助 收藏

Systemic miR-26a deficiency attenuates pulmonary fibrosis via PTEN upregulation and downstream TIMP-1 suppression

系统性 miR-26a 缺乏通过上调 PTEN 和抑制下游 TIMP-1 来减轻肺纤维化

期刊:Molecular Therapy-Nucleic Acids
影响因子:6.1
doi:10.1016/j.omtn.2025.102765
Hamada, Arisa; Shimoji, Kiyofumi; Nakashima, Taku; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Iwamoto, Hiroshi; Hamada, Hironobu; Guo, Yun; Yasuda, Tomoharu; Miyaki, Shigeru; Hattori, Noboru
PTEN
TIMP-1
TIM
发表日期：2025
文献求助 收藏

Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer

循环总 VEGF-A 和 VEGF-A 亚型对非小细胞肺癌患者抗 PD-1/PD-L1 抗体疗效的预测价值

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17040572
Hirakawa, Tetsu; Yamaguchi, Kakuhiro; Funaishi, Kunihiko; Shimoji, Kiyofumi; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Yamada, Shingo; Hattori, Noboru
肺癌
肿瘤
肿瘤免疫
细胞生物学
EGF
VEGF-A
PD-L1
VEGF
PD-1
发表日期：2025
文献求助 收藏

Impact of 2018 Japan floods on allergic rhinitis prescriptions

2018年日本洪灾对过敏性鼻炎处方的影响

期刊:World Allergy Organization Journal
影响因子:4.3
doi:10.1016/j.waojou.2025.101051
Konishi, Hanae; Iwamoto, Hiroshi; Yoshida, Shuhei; Horimasu, Yasushi; Ohshimo, Shinichiro; Takemoto, Kota; Hattori, Noboru; Takeno, Sachio; Matsumoto, Masatoshi
鼻炎
发表日期：2025
文献求助 收藏

Serum Soluble Toll-Like Receptor 4 is a Predictive Biomarker for Acute Exacerbation and Prognosis of Idiopathic Pulmonary Fibrosis: A Retrospective Study

血清可溶性 Toll 样受体 4 是特发性肺纤维化急性加重和预后的预测性生物标志物：一项回顾性研究

期刊:Lung
影响因子:3.9
doi:10.1007/s00408-025-00800-y
Kitadai, Erika; Yamaguchi, Kakuhiro; Iwamoto, Hiroshi; Shimoji, Kiyofumi; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Ohshimo, Shinichiro; Hamada, Hironobu; Hattori, Noboru
信号转导
Toll-Like Receptor
特发性肺纤维化
发表日期：2025
文献求助 收藏

HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC

HMGB1有助于提高肿瘤PD-L1表达对非小细胞肺癌中抗PD-1/PD-L1抗体疗效的预测价值。

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-025-04751-2
Funaishi, Kunihiko; Yamaguchi, Kakuhiro; Tanahashi, Hiroki; Kurose, Koji; Sakamoto, Shinjiro; Horimasu, Yasushi; Masuda, Takeshi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Oga, Toru; Oka, Mikio; Hattori, Noboru
肺癌
肿瘤
肿瘤免疫
PD-L1
HMGB1
细胞生物学
PD-1
发表日期：2025
文献求助 收藏

Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib

两例表皮生长因子受体L861R突变阳性肺腺癌患者接受奥希替尼和阿法替尼治疗的病例报告

期刊:Cancer Reports
影响因子:1.9
doi:10.1002/cnr2.70420
Kagawa, Kei; Masuda, Takeshi; Shimoji, Kiyofumi; Yamaguchi, Kakuhiro; Sakamoto, Shinjiro; Horimasu, Yasushi; Nakashima, Taku; Iwamoto, Hiroshi; Hamada, Hironobu; Hattori, Noboru
信号转导
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏